Theraclion announces strong uptake in echotherapy treatments

Theraclion announces strong uptake in echotherapy treatments

Press releases may be edited for formatting or style | May 25, 2016
MALAKOFF, 24 May 2016 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today strong uptake in the number of echotherapy treatments performed around the world. Since introduction of echotherapy in 2004, 620 treatments have been performed including a major acceleration of treatment activities observed in the past 4 months.

Initially utilized for clinical investigation purposes only in 2004, treatment volume increased meaningfully in 2013 when the first system received marketing authorization. In 2015, a commercialization inflexion point was achieved with 16 commercial agreements in place with recognizable continuation of this trend in 2016.

Observed commercial success has now translated into clinical adoption: in the first 4 months of 2016, +115% more treatments have been performed compared to the same period in 2015. 2016 treatments represent 18% of overall clinical activity to date.

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

In particular, the number of thyroid echotherapy treatments increased eightfold over the first four months of 2016 compared to the same period in 2015. Echotherapy is particularly interesting for the treatment of thyroid nodules, representing for Germany alone a cost savings potential of up to 50% compared to standard surgery. In addition, echotherapy is an ambulatory procedure requiring 1-2 hours versus 3 to 5 days of hospitalization following conventional surgery.

Germany is Theraclion’s strongest market with 8 sites now offering echotherapy to patients and about one quarter of all global treatments performed there. 16 agreements with health insurers assure coverage and patient access to echotherapy treatments for breast fibroadenoma and benign thyroid nodules.

The region with the biggest market potential is Asia, with a particular focus on China and Korea. According to a peer reviewed scientific study1, the market in China is of particular importance with almost 1 million thyroid surgeries performed every year. Within the $6-8 billion annual thyroid surgery market world-wide, China spends nearly $2 billion on thyroid surgical procedures representing a large opportunity for healthcare spend reduction using non-invasive techniques.

“We are pleased to see our growth materializing with significant clinical adoption of echotherapy in our installed base enabling more patient access to non-invasive treatment. Enhanced access to the German and Asian thyroid markets reflects a key inflexion point in our commercial expansion.” says David Caumartin, CEO of Theraclion.

Back to HCB News

You Must Be Logged In To Post A Comment